CA2488617A1 - Nanoparticulate sterol formulations and sterol combinations - Google Patents

Nanoparticulate sterol formulations and sterol combinations Download PDF

Info

Publication number
CA2488617A1
CA2488617A1 CA002488617A CA2488617A CA2488617A1 CA 2488617 A1 CA2488617 A1 CA 2488617A1 CA 002488617 A CA002488617 A CA 002488617A CA 2488617 A CA2488617 A CA 2488617A CA 2488617 A1 CA2488617 A1 CA 2488617A1
Authority
CA
Canada
Prior art keywords
less
sterol
composition
ammonium chloride
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002488617A
Other languages
English (en)
French (fr)
Inventor
Eugene R. Cooper
Laura J. Kline
Gary G. Liversidge
Niels P. Ryde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Pharma International DAC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2488617A1 publication Critical patent/CA2488617A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11Plant sterols or derivatives thereof, e.g. phytosterols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002488617A 2002-06-10 2003-06-10 Nanoparticulate sterol formulations and sterol combinations Abandoned CA2488617A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38732402P 2002-06-10 2002-06-10
US60/387,324 2002-06-10
PCT/US2003/015410 WO2003103633A1 (en) 2002-06-10 2003-06-10 Nanoparticulate sterol formulations and sterol combinations

Publications (1)

Publication Number Publication Date
CA2488617A1 true CA2488617A1 (en) 2003-12-18

Family

ID=29736293

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002488617A Abandoned CA2488617A1 (en) 2002-06-10 2003-06-10 Nanoparticulate sterol formulations and sterol combinations

Country Status (6)

Country Link
US (1) US20040033202A1 (https=)
EP (1) EP1511468A1 (https=)
JP (1) JP2005531606A (https=)
AU (1) AU2003241478A1 (https=)
CA (1) CA2488617A1 (https=)
WO (1) WO2003103633A1 (https=)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20080102121A1 (en) * 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
CA2475092C (en) * 2002-02-04 2012-05-01 Baudax Bio, Inc. Nanoparticulate compositions having lysozyme as a surface stabilizer
AU2003245313A1 (en) * 2002-06-10 2003-12-22 Elan Pharma International, Ltd Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
MXPA04012456A (es) * 2002-06-12 2005-02-17 Coca Cola Co Bebidas que contienen esteroles vegetales.
US7306819B2 (en) * 2002-06-12 2007-12-11 The Coca-Cola Company Beverages containing plant sterols
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
EP1795257B1 (en) 2003-07-17 2013-05-08 Unilever N.V. Method of stabilizing an edible dispersion comprising oil
US8100822B2 (en) 2004-03-16 2012-01-24 Macroplata Systems, Llc Anoscope for treating hemorrhoids without the trauma of cutting or the use of an endoscope
US8968768B2 (en) 2004-03-29 2015-03-03 Wyeth Llc Phytosterol nutritional supplements
PL1732605T3 (pl) * 2004-03-29 2019-09-30 Wyeth Llc Multiwitaminowe i mineralne suplementy odżywcze
CA2590675A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
KR20070118224A (ko) * 2005-01-06 2007-12-14 엘란 파마 인터내셔널 리미티드 나노입자형 칸데사르탄 제제
US20080206407A1 (en) * 2005-01-14 2008-08-28 Veldhuizen Yvonne Susanna J Sachets Comprising Plant Sterol
MX2007009915A (es) * 2005-02-15 2007-11-06 Elan Pharma Int Ltd Formulaciones en aerosol e inyectables de benzodiazepina nanoparticulada.
EP1850676A1 (en) 2005-02-17 2007-11-07 Unilever N.V. Granules comprising sterol
CA2598288A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
JP5096138B2 (ja) * 2005-03-31 2012-12-12 サントリーホールディングス株式会社 リグナン類化合物含有水中油滴型エマルション及びそれを含有する組成物
EP1871345B1 (en) 2005-04-12 2012-08-01 Elan Pharma International Limited Nanoparticulate erlotinib formulations
KR20080008403A (ko) * 2005-05-10 2008-01-23 엘란 파마 인터내셔널 리미티드 나노입자형 클로피도그렐 제제
US20110064803A1 (en) * 2005-05-10 2011-03-17 Elan Pharma International Limited. Nanoparticulate and controlled release compositions comprising vitamin k2
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
BRPI0611075A2 (pt) * 2005-06-03 2010-08-03 Elan Pharma Int Ltd formulações de acetaminofeno em nanopartìcula
ES2341996T3 (es) * 2005-06-03 2010-06-30 Elan Pharma International Limited Formulaciones de mesilato de imatinib en forma de manoparticulas.
EP1954253A4 (en) 2005-06-08 2011-07-27 Elan Pharma Int Ltd NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
EP1898882B1 (en) * 2005-06-09 2009-10-28 Elan Pharma International Limited Nanoparticulate ebastine formulations
CA2611741A1 (en) * 2005-06-13 2006-12-28 Elan Pharma International, Limited Nanoparticulate clopidogrel and aspirin combination formulations
JP2008543862A (ja) * 2005-06-15 2008-12-04 エラン ファーマ インターナショナル リミテッド ナノ粒子アゼルニジピン製剤
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
BRPI0613631A8 (pt) * 2005-07-18 2017-12-26 Univ Massachusetts Lowell nanoemulsão e método,
DE102005039835A1 (de) * 2005-08-23 2007-03-01 Cognis Ip Management Gmbh Pulverförmige Sterolformulierungen mit Kolloidbildnern
US20070104792A1 (en) * 2005-09-13 2007-05-10 Elan Pharma International, Limited Nanoparticulate tadalafil formulations
CA2622758A1 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
BRPI0619134B8 (pt) 2005-12-01 2021-05-25 Univ Massachusetts Lowell nanoemulsão, composição farmacêutica, composição, métodos cosméticos para o tratamento de rugas, linhas faciais e/ou linhas do pescoço, e de retardar o início das rugas, linhas faciais e/ou linhas do pescoço, e, método de fabricação de uma nanoemulsão
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
JP5147699B2 (ja) * 2005-12-20 2013-02-20 富士フイルム株式会社 タンパク質ナノ粒子およびその使用
US8017153B2 (en) * 2006-02-07 2011-09-13 U.S. Nutraceuticals, LLC Dietary supplement composition for blood lipid health
US8202541B2 (en) * 2006-02-07 2012-06-19 U.S. Nutraceuticals, LLC Dietary supplement composition for blood lipid health
JP2009538927A (ja) 2006-05-30 2009-11-12 エラン ファーマ インターナショナル,リミティド ナノ粒子状のポサコナゾール製剤
JP2009543797A (ja) * 2006-07-10 2009-12-10 エラン ファーマ インターナショナル,リミティド ナノ粒子ソラフェニブ製剤
KR20090031618A (ko) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 나노입자형 모다피닐 제제
US20100063142A1 (en) * 2006-10-04 2010-03-11 Toshihiro Nishiumi o/w/o EMULSION CONTAINING LIGNAN COMPOUNDS AND COMPOSITION CONTAINING THE SAME
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
SG10201607909WA (en) * 2006-12-01 2016-11-29 Anterios Inc Peptide nanoparticles and uses therefor
WO2008070538A2 (en) * 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
EP2067410A1 (en) 2007-12-07 2009-06-10 Cognis IP Management GmbH Water-dispersable sterol containing dispersion
MX2010010050A (es) 2008-03-20 2011-03-15 Virun Inc Star Emulsiones que incluyen un derivado de polietilen glicol de tocoferol.
MX2010009848A (es) * 2008-03-21 2010-09-30 Elan Pharma Int Ltd Composiciones para el suministro especifico en sitio de imatinib y metodos de uso.
WO2010008475A2 (en) * 2008-06-23 2010-01-21 Virun, Inc. Compositions containing nono-polar compounds
MX379265B (es) * 2008-06-26 2025-03-11 Anterios Inc Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel.
PL2367434T3 (pl) 2008-12-19 2017-09-29 Unilever BCS Europe B.V. Jadalne tłuszczowe proszki
US8287936B2 (en) 2009-02-17 2012-10-16 Kraft Foods Global Brands Llc Bake-stable creamy food filling base
HUE032426T2 (en) 2009-05-27 2017-09-28 Alkermes Pharma Ireland Ltd Inhibition of flake aggregation in nanoparticulate meloxicam formulations
CN103037708B (zh) 2010-03-23 2015-05-20 维尔恩公司 含有蔗糖脂肪酸酯的纳米乳液
US8632458B2 (en) 2011-10-26 2014-01-21 Macroplata Inc. Gentle hemorrhoid treatment offering a substantially painless healing
WO2011139665A2 (en) 2010-04-26 2011-11-10 Macroplata, Inc. Apparatus and method for effecting at least one anatomical structure
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
PL2584907T3 (pl) 2010-06-22 2014-10-31 Unilever Bcs Europe Bv Proszek jadalnego tłuszczu
US20130177651A1 (en) * 2010-09-03 2013-07-11 Pharmaterials Limited Pharmaceutical Composition Suitable for Use in a Dry Powder Inhaler
PH12013500547A1 (en) 2010-09-22 2013-06-10 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
MX342040B (es) 2010-12-17 2016-09-12 Unilever Nv Emulsion de agua en aceite comestible.
US20130266715A1 (en) 2010-12-17 2013-10-10 René Joachim Buter Process of compacting a microporous fat powder and compacted fat powder so obtained
EP2811847B1 (en) 2012-02-10 2017-12-13 Virun, Inc. Beverage compositions containing non-polar compounds
NZ742005A (en) * 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
HK1213780A1 (zh) * 2013-03-04 2016-07-15 Vtv治疗有限责任公司 穩定的葡萄糖激酶活化劑組合物
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
ES2891151T3 (es) * 2014-02-03 2022-01-26 Apurano Pharmaceuticals Gmbh Nanosuspensión de materiales naturales y método para su preparación
LT3169322T (lt) * 2014-07-18 2020-12-10 Berlin-Chemie Aktiengesellschaft Dietinė kompozicija su atidislipideminiu aktyvumu
CN106604732A (zh) * 2014-09-02 2017-04-26 雀巢产品技术援助有限公司 二氢胆固醇的用途
MX386419B (es) 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
FR3091706B1 (fr) * 2019-01-10 2021-10-01 Arkema France Composition d’huile végétale pour l’enrobage de particules
PL3928772T3 (pl) 2020-06-26 2024-10-07 Algiax Pharmaceuticals Gmbh Kompozycja nanocząstkowa
US11285108B1 (en) * 2021-03-09 2022-03-29 Naturalis S.A. Phytosterols for the prevention or treatment of non-alcoholic steatohepatitis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3085939A (en) * 1959-05-11 1963-04-16 Upjohn Co Oil-in-water emulsion for oral administration, and process for preparation
US3489698A (en) * 1967-05-03 1970-01-13 Union Carbide Corp Stable emulsions of incompatible polyols containing ethylene oxide-propylene oxide block copolymers as emulsifiers
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
IE970731A1 (en) * 1997-10-07 2000-10-04 Fuisz Internat Ltd Product and method for the treatment of hyperlipidemia
US5932562A (en) * 1998-05-26 1999-08-03 Washington University Sitostanol formulation to reduce cholesterol absorption and method for preparing and use of same
AU5745599A (en) * 1998-09-15 2000-04-03 Henkel Kommanditgesellschaft Auf Aktien Method for producing nanoparticles
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
EP1121088B1 (de) * 1998-10-14 2002-12-18 Cognis Deutschland GmbH & Co. KG Verwendung von nanoskaligen sterolen und sterolestern
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
CA2377492A1 (en) * 1999-06-23 2001-01-04 Honming Chen Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
AU5405200A (en) * 1999-06-25 2001-01-31 Cognis Deutschland Gmbh & Co. Kg Use of nanoscale sterols and sterol esters
JP4229548B2 (ja) * 1999-11-16 2009-02-25 東レ・ダウコーニング株式会社 化粧品、および化粧品の製造方法
KR20020026053A (ko) * 2000-09-30 2002-04-06 노승권 음료용 식물성 스테롤의 분산방법 및 이를 함유하는 음료
NZ527408A (en) * 2001-02-22 2005-04-29 Skyepharma Canada Inc Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
US20030003131A1 (en) * 2001-06-22 2003-01-02 Matthew Dyer Method for manufacture of free-flowing powder containing water-dispersible sterols
US20030203854A1 (en) * 2002-04-23 2003-10-30 Ivo Pischel Composition for effecting serum cholesterol levels

Also Published As

Publication number Publication date
US20040033202A1 (en) 2004-02-19
WO2003103633A1 (en) 2003-12-18
EP1511468A1 (en) 2005-03-09
JP2005531606A (ja) 2005-10-20
AU2003241478A1 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
US7763278B2 (en) Nanoparticulate polycosanol formulations and novel polycosanol combinations
US20040033202A1 (en) Nanoparticulate sterol formulations and novel sterol combinations
CA2488499C (en) Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"),combinations thereof as well as manufacturing of these pharmaceutical compositions
CA2487054C (en) Nanoparticulate fibrate formulations
US20110027371A1 (en) Nanoparticulate statin formulations and novel statin combinations
US7320802B2 (en) Methods of treatment using nanoparticulate fenofibrate compositions
US20080213378A1 (en) Nanoparticulate statin formulations and novel statin combinations
AU2006309295B2 (en) Nanoparticulate acetaminophen formulations
JP2006508105A5 (https=)
WO2006069098A1 (en) Nanoparticulate bicalutamide formulations
CA2612384A1 (en) Nanoparticulate azelnidipine formulations
ZA200410209B (en) Nanoparticulate fibrate formulations

Legal Events

Date Code Title Description
FZDE Discontinued